Are TYK2 inhibitors ‘ticked’ to be part of the JAK family? Are Tyk2 inhibitors JAK inhibitors? Yes, no, maybe Check out all of Dr. Janet Pope’s TYK2 Q&A. https://t.co/IqeGqt6M4t https://t.co/kjWLVKVFP7

• https://bit.ly/3m4xiOT

GM-CSF increased in patients with active ankylosing spondylitis, correlates with disease activity, not duration. TNFi does not affect GM-CSF levels. Could explain efficacy of JAKinibs and response for residual inflammation during TNF blockade. @RheumNow #EULAR2022 ABST#OP0107

JAKi for nonradiographic axSpA One area of continued interest for many rheumatologists is the field of non-radiographic axial spondyloarthritis. And the question of the utility of JAK inhibitors for the treatment of axSpA has been on the rise. https://t.co/xq8ICyKKv0 https://t.co/o2iUgyU60A

• https://bit.ly/3PZZccS

#EULAR2022 ASAS/EULAR AxSpA Recs ⭐️Last: 2016 ▶️All: education, exercise, 🚭 ▶️❌csDMARD for axial disease ▶️TNF/IL17 (or JAK) with high disease: ASDAS>/=2.1 ▶️Monoclonal TNF for uveitis/IBD, high PsO: IL-17 ▶️Sustained remission: tapering of bDMARD "can be considered" @RheumNow https://t.co/3yYU0Vb37r

RABBIT registry data on CV events with JAKi. Incidence rate low 0.41/100PY. No increase compared to TNFi RR 0.94 (0.39-2.38). No increase in high-risk group RR 0.90 (0.37-2.17). Reassuring with wide CI's. @RheumNow #EULAR2022 OP0135 https://t.co/vBSsnfeBoR https://t.co/iYDZsNwMye

• EULAR Abstract Archive

#EULAR2022 OP0135: German RABBIT 🐇 Registry: ⭐️ Observational, 46% Tofa, 54% Bari No increased rate of CVD in JAK vs TNF inhibitor 🚨Unlike the ORAL Surveillance @RheumNow https://t.co/O4IXg22Ybc

RABBIT registry and MACE in RA No difference between *JAKi (Tofa and Bari) and *TNFi in both unselected and high CV risks patients. 🧨 different than ORAL surveillance but Observational and overall Low incidence (28 events). #EULAR2022 @RheumNow OP0135 https://t.co/o8rngHrwQF

Upadacitinib shows promising response in the treatment of nr-AxSpA in the SELECT-AXIS 2 study. Deodhar et al showed the ASAS40 response rate for UPA was twice vs placebo (45% vs 23%). 12/14 of the secondary endpoints were also met #EULAR2022 @RheumNow OP0016 https://t.co/dOWVJdLRtG